Edison Investment Research

Latest research

Sunesis Pharmaceuticals

Dosing update at ASH

Update | Pharmaceutical & healthcare | 09/11/2018

Sunesis released its abstracts for the upcoming American Society of Hematology (ASH) meeting, which included an update on the company’s ongoing Phase Ib/II trial of vecabrutinib in hematologic cancers. The study is still in the dosing portion of the trial on the 50mg arm, but the data to date showed a safety and tolerability profile in line with expectations. The company will provide a complete update of the trial progress at ASH.

Endeavour Mining

Maiden resource paves way for potential project

Update | Mining | 09/11/2018

On 29 October, Endeavour (EDV) announced a maiden resource at its Fetekro property in north central Côte d’Ivoire of 719koz Au, contained within 9.8Mt. The resource equates to 4.0% of Endeavour’s prior, global resource (on a 100% basis), or 4.8% on an attributable basis. However, it equates to a rather more significant 4.5-7.6% of Endeavour’s 9.5-16.0Moz exploration target over the course of the next five years. Moreover, at 2.25g/t, its average grade is 21.0% above the average…

Martin Currie Asia Unconstrained Trust

Deep discount and attractive yield

Review | Investment Companies | 09/11/2018

Martin Currie Asia Unconstrained Trust (MCP) aims to deliver growth in line with nominal Asia ex-Japan GDP on a rolling three-year basis. It follows a detailed, bottom-up approach to investing in a concentrated portfolio of 20–30 of Asia’s highest-quality and most sustainable businesses, unconstrained by a benchmark. Although market conditions have become more challenging for Asian equities, MCP’s manager Andrew Graham believes the portfolio’s high-quality companies are poised…

Pluristem Therapeutics

FY18 results and top-line claudication data

Update | Pharmaceutical & healthcare | 07/11/2018

Pluristem ended FY18 with an operating loss of $33.7m mostly attributed to R&D expenditure ($22.6m) and as of 30 June 2018 had $30.6m in net cash. The company recently announced its plans to present at several November conferences, including top-line data from its Phase II intermittent claudication (IC) study at the American Heart Association (AHA) Scientific Sessions, as well as an overview of its cell therapy products in clinical development at BioEurope.

BioPharma Credit

Oversubscribed offering fuels further growth

Review | Investment Companies | 06/11/2018

BioPharma Credit (BPCR) provides access to a diverse portfolio of debt instruments for life science companies, consisting mainly of senior secured loans at present. Structural changes in the industry and high M&A activity constitute positive drivers of BPCR’s new debt investments. Despite increased life sciences equity and convertible bonds issues, the trust has invested c US$640m so far this year (and has outstanding commitments of US$140.5–160.5m). The trust has recently completed…

Edison North America